Full Press Release Details
argenx to Present Data from Phase 2 Trial of Efgartigimod in Pemphigus at 2020 Society for Investigative Dermatology (SID) Virtual Annual Meeting.
ARGX
argenx to Present Data from Phase 2 Trial of Efgartigimod in Pemphigus at 2020 Society for Investigative Dermatology (SID) Virtual Annual Meeting
Key Takeaway: argenx to Present Data from Phase 2 Trial of Efgartigimod in Pemphigus at 2020 Society for Investigative Dermatology (SID) Virtual Annual Meeting
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+42%
120-day peak, hindsight
Typical move
4%
average across 14 past catalysts
Lead asset
Empasiprubart
Phase 2 · Dermatomyositis